Phare Bio receives funding to further develop its AI drug discovery platform

Phare Bio and Collins Lab are collaborating to develop a first-ever open-source database for AI-driven antibiotic discovery. Photo credit: Gorodenkoff/Shutterstock.

Phare Bio, in collaboration with MIT's Collins Lab and Harvard University's Wyss Institute, has received $27 million from the Advanced Research Projects Agency for Health (ARPA-H) to advance its AI-powered drug discovery platform and develop new classes of antibiotics .

The funding aims to address the urgent need for new antibiotics in the face of the growing antimicrobial resistance (AMR) crisis, which poses a significant threat to global health.

The company's recent breakthrough with Collins Lab in generative AI-based antibiotic design represents a significant leap in the ability to customize and precisely develop new antibiotics.

The ARPA-H grant will enable several important developments at Phare Bio and Collins Lab. They plan to generate millions of new training data points for various drug development parameters such as toxicology and drug metabolism.

The companies will improve the clinical precision of AI-based drug discovery.

Dr. Akhila Kosaraju, CEO and President of Phare Bio, said: “The AMR crisis is accelerating, but with this collaboration with ARPA-H another door opens.”

Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive advantage.

Company profile – free sample

Your download email will arrive shortly

We are convinced of the unique quality of our company profiles. However, because we want you to make the most beneficial decision for your business, we offer you a free sample that you can download by filling out the form below

By GlobalData

Click here to unsubscribe from Pharmaceutical Technology's curated industry news, reports and event updates.

Visit our Privacy Policy for more information about our Services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can opt-out of future marketing communications. Our Services are intended for corporate subscribers and you warrant that the email address provided is your corporate email address.

“These funds will enable Phare Bio to bring unprecedented clinical precision to our generative AI discovery platform and develop the novel and specific antibiotics that patients and physicians so urgently need.”

Phare Bio and Collins Lab aim to create the first open source database for AI-based antibiotic discovery by sharing their expertly curated datasets. This initiative is expected to advance the research efforts of the next generation of antibiotic researchers.

The collaboration will also integrate up to ten new “filters” into Phare Bio’s generative AI drug discovery engine. These filters are designed to produce new and targeted antibiotics against specific bacterial diseases, including pneumonia, drug-resistant urinary tract infections and sepsis.

The funding will also support the further development of 15 new AI-generated preclinical antibiotic candidates.